Caricamento...
晚期EGFR突变型非小细胞肺癌患者接受吉非替尼或厄洛替尼治疗的成本效益分析
BACKGROUND AND OBJECTIVE: Targeted therapy in non-small cell lung cancer (NSCLC) had become a research hotspot.Both of gefitinib and erlotinib had already been recommended as first line treatment in epidermal growth factor receptor (EGFR) mutant advanced NSCLC patients.The study aimed to compare the...
Salvato in:
| Pubblicato in: | Zhongguo Fei Ai Za Zhi |
|---|---|
| Natura: | Artigo |
| Lingua: | Inglês |
| Pubblicazione: |
中国肺癌杂志编辑部
2013
|
| Soggetti: | |
| Accesso online: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6000588/ https://ncbi.nlm.nih.gov/pubmed/23601301 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3779/j.issn.1009-3419.2013.04.06 |
| Tags: |
Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !
|